EpitogenX: embracing disruption through innovative technologies.
EpitogenX is a forward-thinking biotech with innovative platforms backed by a world-leading scientific team. We strive to improve global healthcare outcomes by offering innovative solutions and affordable products.
EpitogenX Ltd is a holding company aiming to build on the successes of its subsidiary, Vertebrate Antibodies Ltd, to transform the biotech industry by providing high-quality services and products for both the medical and veterinary sectors.
Our EpitoGen® and AI EpitoPrediktTM technologies come together to create a powerful game-changing platform that will transform diagnostics, vaccine design, biotherapeutics, and antibody development.
With the support of Innova Medical Group Inc, we also aim to provide accurate, simple, accessible, and affordable point-of-care testing systems.
Using AI models we offer in silico solutions, validated in vitro and applied to create prototype clinical products using EpitoGen® Technology.
Products developed using this technology are compatible with gold standard lab-based and point-of-care applications (i.e. ELISA, LFA, microfluidics), making them affordable and user friendly.
“To improve life by making accurate and affordable products accessible to community-based healthcare and middle/low-income countries”. At EpitogenX we are very proud of the important role we will play in providing our partners with the means to deliver clinical products.
“Our Vision is to make our game-changing EpitoGen® technology available globally to transform the diagnostic sector”
Strategic visionary and entrepreneur, Ayham Alnabulsi is a co-founder of EpitoGenX and its CTO. Previously, Ayham has also co-founded and led Vertebrate Antibodies and AiBiologics. Ayham has extensive knowledge in medical genetics, immunology and mathematics, and he is a co-inventor of the game-changer EpitoGen technology.
Dr. Abdo is a co-founder, director and CEO of EpitogenX Ltd. He previously co-founded AiBiologics and Vertebrate Antibodies, and served as COO and CSO respectively. Abdo has a unique combination of scientific, financial and commercial expertise with a successful track record in molecular medicine, biomarker discovery, bio-product development, bioinformatics and immunoassays optimisation.
Tiehui Wang is a co-founder of the company and brings dynamic technology innovation and insight from his 30 years+ experience in protein engineering. Tiehui has valuable expertise in medical technology innovation as the co-inventor of the game changing EpitoGen® platform. Previously, Tiehui cofounded AiBiologics and served as a Chief Scientist.
Yehfang Hu is an immunologist with a wealth of expertise on veterinary immunology, immunopathology and IVD product development.
Alex Wang joined the team in 2022 with expertise in the development and optimization of novel point-of-care testing platforms. Alex has a background in medical sciences with experience in biotechnology and medical applications.
Dr Falconer holds a BSc Honours in Microbiology, MSc in Medicine and therapeutics and PhD in Cognitive Neuroscience. He has been a researcher for nearly 2 decades having worked extensively in both the scientific and social sciences fields. His scientific and academic knowledge is backed up by various publications in scientific papers. He is also a playwright and has authored and produced many plays across the UK.
Steve brings extensive epxertise in the understanding of the molecular mechanisms determining the impact of pathogenic microorganisms on the immune system of lower vertebrates. Steve is a leading expert in vaccine development and immunostimulant research for enhanced aquatic animal health and sustainability.
Megan brings a combination of scientific, Research and Development experience to EpitoGenx. She is also an expert in Medical Sciences with a strong background in biomarker identification and assay development.
Rodanthi’s expertise includes the creation of data algorithms and specialized bioinformatics pipelines using DNA and protein sequences in order to identify actionable clinical signatures. Rodanthi will aid in the building a diagnostic serology-based test for Type 1 Diabetes.
Professor Murray is Emeritus Regius Professor of Anatomy. He was the lead consultant gastro-intestinal pathologist to NHS Grampian and for the Grampian Biorepository. Professor Murray is an internationally recognised pathologist with specific interests in gastro-intestinal pathology and antibody technologies.
Wei Pang (Associate Professor, Heriot-Watt University) is a computer scientist who is specialised in Bio-inspired Computing, Machine Learning, and Explainable AI. Wei will apply bio-inspired computing approaches to optimise existing AI tools and develop novel machine learning and data mining algorithms.
Professor Secombes (Emeritus Regius Chair of Natural History) is a renowned immunologist with a wealth of expertise on veterinary immunology and immunopathology.
Professor Secombes has made a lasting contribution to the characterisation and elucidation of immune systems in lower vertebrates, influencing in the process disease mitigation and vaccine development.
Ting-Yu brings a wealth of expertise in biology, biotechnology, proteome exploration and metabolomics analyses. Ting-Yu is an expert in investigating proteomics ans metabolics processes using the liquid-chromatography mass spectrometry (LC-MS/MS) platforms. This set of skills are ideal to quantify disease markers and establish accurate diagnostic products
Professor Mirela Delibegovic, Regius Chair of Physiology, FRSE, Director of Aberdeen Cardiovascular and Diabetes Research Center. Mirela has a vast experience in metabolic diseases and cell signalling. She leads many translational projects including drug discovery using bioinformatic and medicinal chemistry approaches, in vitro and in vivo pre-clinical testing, patient derived organoid cultures and patient populations.
Dr Brittain-Long is a consultant physician with >25 years of clinical experience. He is a specialist in Infectious Diseases, General Medicine & Acute Medicine with an interest in diagnostics, from the molecular level to direct clinical care. His research & clinical expertise includes tick-borne infections, respiratory viruses, TB and NTM.
We offer in silico and in vitro technologies that can accelerate the development of antibody-based assays, improve assay performance, and reduce cost and lead production time. Our novel technology has been created to overcome the main technical issues that have hindered the development of accurate serological tests.
By virtue of the multiplexing capacity of our platform, we can develop break-through diagnostic products. For example, EpitoPrediktTM can isolate allergy associated epitopes, paving the way for the development of effective allergy testing.
EpitoGen® scaffold provides a superior framework to express and display antibody fragments for diagnostic testing. EpitoGen® also increases production yield, improves stability, and reduces cost.
Importantly, the scaffold is engineered to bind preferentially to testing surfaces, ensuring correct orientation of the displayed paratope, consequently improving assay performance.
EpitoPrediktTM and EpitoGen® can be used together to accelerate the development of epitope/subunit-based vaccines whilst offering significant safety advantages. EpitoPrediktTM ‘s ability to identify B-cell, CTL and HTL epitopes enhances the efficacy of current vaccine platforms, whilst EpitoGen®‘s multiplexing capacity further improves efficacy and provides an efficient delivery system for vaccine candidates.
Our AI software can also identify immune components that will support mucosal vaccine design (i.e. IgA-rich antigens).
Both platforms (EpitoGen® and EpitoPrediktTM) provide in silico and in vitro screening for potential immunogenic signatures of biological candidates for clinical evaluation.
We can identify immunogenic signatures for the lead candidates to carry forward from preclinical and clinical trials, which improves overall safety and reduces the risk of failure due to immunogenicity issues.
Nanobodies can be expressed and displayed on our EpitoGen® scaffolds to improve stability and reduce the cost of production.
Using our EpitoGen® Scaffolds, multiple immunogen epitopes can be displayed and used to improve the efficiency and quality of antibody development.
“Our unique technology uses artificial intelligence and deep learning models to provide breakthrough solutions that will revolutionise the fields of diagnostics, vaccine designs and therapeutics evaluation.”
EpitogenX brings together two innovative platforms to create game-changing solutions.
EpitoPrediktTM is an AI software that can accurately identify immunodominant epitopes, a crucial component of diagnostic, prophylactic and immunotherapeutic vaccines.
The software is embedded with machine and deep learning algorithms which generate models that can provide accurate solutions for specific biological designs.
Our core technology is called EpitoGen®; a bioengineered recombinant scaffold that can display single or multiple epitopes/antigens, forming the basis of the diagnostic assay.
Both platforms create a self-learning system whereby data generated experimentally is used to train the AI models and improve their predictive accuracy.
Learn more about our current projects, the applications of our technology and the company news.
EpitogenX is thrilled to announce the launch of its cutting-edge Lyme Disease Diagnostic Kit. This advanced diagnostic tool is set to revolutionize Ly
Lyme Borreliosis, commonly known as Lyme disease, poses a significant health threat worldwide. The condition stems from infection by the bacterial spe
EpitogenX is delighted to announce the launch of an Innovate UK Knowledge Transfer Partnership (KTP) between our subsidiary, Vertebrate Antibodies, an